2025
Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort
Jayavelu N, Qi J, Milliren C, Ozonoff A, Liu S, Levy O, Baden L, Melamed E, McComsey G, Cairns C, Schaenman J, Shaw A, Hafler D, Corry D, Kheradmand F, Atkinson M, Brakenridge S, Higuita N, Metcalf J, Hough C, Messer W, Pulendran B, Nadeau K, Davis M, Geng L, Sesma A, Simon V, Krammer F, Bime C, Calfee C, Bosinger S, Eckalbar W, Steen H, Maecker H, Becker P, Augustine A, Holland S, Rosen L, Lee S, Vaysman T, Ozonoff A, Diray-Arce J, Chen J, Kho A, Milliren C, Hoch A, Chang A, McEnaney K, Barton B, Lentucci C, Murphy M, Saluvan M, Shaheen T, Liu S, Syphurs C, Albert M, Hayati A, Bryant R, Abraham J, Thomas S, Cooney M, Karoly M, Altman M, Jayavelu N, Presnell S, Kohr B, Jancsyk T, Arnett A, Peters B, Overton J, Vita R, Westendorf K, Overton J, Levy O, Steen H, van Zalm P, Fatou B, Smolen K, Viode A, van Haren S, Jha M, Stevenson D, Odumade O, Baden L, Mendez K, Lasky-Su J, Tong A, Rooks R, Desjardins M, Sherman A, Walsh S, Mitre X, Cauley J, Li X, Evans B, Montesano C, Licona J, Krauss J, Issa N, Chang J, Izaguirre N, Hutton S, Michelotti G, Wong K, Tebbutt S, Shannon C, Sekaly R, Fourati S, McComsey G, Harris P, Sieg S, Ribeiro S, Cairns C, Haddad E, Kutzler M, Bernui M, Cusimano G, Connors J, Woloszczuk K, Joyner D, Edwards C, Lee E, Lin E, Melnyk N, Powell D, Kim J, Goonewardene I, Simmons B, Smith C, Martens M, Croen B, Semenza N, Bell M, Furukawa S, McLin R, Tegos G, Rogowski B, Mege N, Ulring K, Schearer P, Sheidy J, Nagle C, Seyfert-Margolis V, Rouphael N, Bosinger S, Boddapati A, Tharp G, Pellegrini K, Johnson B, Panganiban B, Huerta C, Anderson E, Samaha H, Sevransky J, Bristow L, Beagle E, Cowan D, Hamilton S, Hodder T, Bechnak A, Cheng A, Mehta A, Ciric C, Spainhour C, Carter E, Scherer E, Usher J, Hellmeister K, Hussaini L, Hewitt L, Mcnair N, Ribeiro S, Wimalasena S, Fernandez-Sesma A, Simon V, Krammer F, Van Bakel H, Kim-Schulze S, Reiche A, Qi J, Lee B, Carreño J, Singh G, Raskin A, Tcheou J, Khalil Z, van de Guchte A, Farrugia K, Khan Z, Kelly G, Srivastava K, Eaker L, Bermúdez-González M, Mulder L, Beach K, Saksena M, Altman D, Kojic E, Sominsky L, Azad A, Bielak D, Kawabata H, Yellin T, Fried M, Sullivan L, Morris S, Kleiner G, Stadlbauer D, Dutta J, Xie H, Patel M, Nie K, Rahman A, Messer W, Hough C, Siegel S, Sullivan P, Lu Z, Brunton A, Strand M, Lyski Z, Coulter F, Micheleti C, Maecker H, Pulendran B, Nadeau K, Rosenberg-Hasson Y, Leipold M, Sigal N, Rogers A, Fernandes A, Manohar M, Do E, Chang I, Lee A, Blish C, Din H, Roque J, Geng L, Artandi M, Davis M, Ahuja N, Yang S, Chinthrajah S, Hagan T, Reed E, Schaenman J, Salehi-Rad R, Rivera A, Pickering H, Sen S, Elashoff D, Ward D, Brook J, Sanchez E, Llamas M, Perdomo C, Magyar C, Fulcher J, Erle D, Calfee C, Hendrickson C, Kangelaris K, Nguyen V, Lee D, Chak S, Ghale R, Gonzalez A, Jauregui A, Leroux C, Altamirano L, Rashid A, Willmore A, Woodruff P, Krummel M, Carrillo S, Ward A, Langelier C, Patel R, Wilson M, Dandekar R, Alvarenga B, Rajan J, Eckalbar W, Schroeder A, Fragiadakis G, Tsitsiklis A, Mick E, Guerrero Y, Love C, Maliskova L, Adkisson M, Leligdowicz A, Beagle A, Rao A, Sigman A, Samad B, Curiel C, Shaw C, Tietje-Ulrich G, Milush J, Singer J, Vasquez J, Tang K, Betancourt L, Santhosh L, Pierce L, Paz M, Matthay M, Thakur N, Rodriguez N, Sutter N, Jones N, Sinha P, Prasad P, Lota R, Rashid S, Asthana S, Bhide S, Lea T, Abe-Jones Y, Hafler D, Montgomery R, Shaw A, Kleinstein S, Gygi J, Pawar S, Konstorum A, Chen E, Cotsapas C, Wang X, Xu L, Dela Cruz C, Iwasaki A, Mohanty S, Nelson A, Zhao Y, Farhadian S, Asashima H, Chaudhary O, Coppi A, Fournier J, Muenker M, Nelson A, Raddassi K, Rainone M, Ruff W, Salahuddin S, Shulz W, Vijayakumar P, Wang H, Wunder E, Young H, Ko A, Wang X, Duchen D, Esserman D, Guan L, Brito A, Rothman J, Grubaugh N, Corry D, Kheradmand F, Song L, Nelson E, Metcalf J, Higuita N, Sinko L, Booth J, Drevets D, Brown B, Kraft M, Bime C, Mosier J, Erickson H, Schunk R, Kimura H, Conway M, Francisco D, Molzahn A, Wilson C, Schunk R, Hughes T, Sierra B, Atkinson M, Brakenridge S, Ungaro R, Manning B, Moldawer L, Oberhaus J, Guirgis F, Borresen B, Anderson M, Ehrlich L, Melamed E, Maguire C, Wylie D, Rousseau J, Hurley K, Geltman J, Siles N, Rogers J, Augustine A, Diray-Arce J, Haddad E, Sekaly R, Kraft M, Woodruff P, Erle D, Ehrlich L, Montgomery R, Becker P, Altman M, Fourati S. Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort. Journal Of Allergy And Clinical Immunology Global 2025, 4: 100515. PMID: 40709330, PMCID: PMC12284355, DOI: 10.1016/j.jacig.2025.100515.Peer-Reviewed Original ResearchT2 immune responseClinical outcomesVirus loadImmune responseSARS-CoV-2Primary siteSusceptibility to respiratory viral infectionsType 2 immune responsesAntibody titersCellular markersPrimary site of infectionSeverity of respiratory illnessRespiratory viral infectionsIL-13 levelsDegree of respiratory supportAssociated with less severe COVID-19Site of infectionLow virus loadSevere COVID-19Effects of SARS-CoV-2Severe coronavirus diseaseDiagnosis of asthmaRespiratory supportCoronavirus severe acute respiratory syndrome coronavirus 2Blood cytometry
2022
Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study
Hay J, Kissler S, Fauver J, Mack C, Tai C, Samant R, Connolly S, Anderson D, Khullar G, MacKay M, Patel M, Kelly S, Manhertz A, Eiter I, Salgado D, Baker T, Howard B, Dudley J, Mason C, Nair M, Huang Y, DiFiori J, Ho D, Grubaugh N, Grad Y. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. ELife 2022, 11: e81849. PMID: 36383192, PMCID: PMC9711520, DOI: 10.7554/elife.81849.Peer-Reviewed Original ResearchConceptsViral kineticsSARS-CoV-2 strainsAntibody titersViral reboundVaccination statusLonger clearance timeLower peak viral loadRetrospective cohort studyClearance timePeak viral loadSARS-CoV-2 variantsHigh antibody titersEffective immune responseRT-qPCR testingBooster vaccinationCohort studyEffect of ageViral loadHealth cohortSymptom statusImmune historyImmune responseInfection historyClearance rateInfectionNeutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply